BioAgilytix now operates 355,000-square-feet of laboratory facilities, including 24,000-square-feet dedicated to LC/MS.

Genomics unveils Mystra at ASHG 2025—an AI genetics platform to accelerate drug discovery and clinical validation using large-scale genetic data.

In this GEN interview, Nobel Laureate David Baker, PhD, emphasizes that designing proteins from scratch is reality and unpacks what's needed for AI to transform medicine.

As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in coming days, analysts and especially investors will keep their eyes on whether the ...

The peptide lab is designed to produce a range of molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates.

Researchers say findings help to bridge the structure of the genome to its function in managing how genes are turned on and off.

Using CRISPR-based genetic engineering, the team further identified mutations in viral genes that prevent activation, ...

Serbia’s BIO4 Campus reflects the convergence biosciences, AI, and IT to power innovation and global collaboration.

A new mechanism explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer.

Scientists suggest approach could be leveraged for a wide range of chemical applications, with complex, workflows streamlined into a rapid, single-step reaction.

Despite economic uncertainty, the CEOs of life science and biotech companies are making artificial intelligence a top ...

Scalable, workflow-optimized solutions will be essential to improving cancer care in emerging and previously underserved ...